Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.